RxDoctor Payments Data

Jessica Roux, MD

Family Medicine · Roeland Park, KSNPI 1922532076

Payments from drug & device makers

$1,287in general payments, 2019–2025

Across 63 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$326
  • Novo Nordisk$202
  • Amgen$187
  • Pfizer$143
  • Lilly USA, LLC$106
  • Astellas Pharma US Inc$76
  • plus $247 from 11 others

What the payments were for

  • Food & beverage$1,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,287 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$96,865
Medicare patients
240
Services billed
2,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$65,023
EliquisApixaban14$23,258
JanuviaSitagliptin Phosphate22$21,776
XareltoRivaroxaban11$18,445
OzempicSemaglutide12$14,659
MounjaroTirzepatide11$13,852
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,810
Rosuvastatin Calcium197$2,269
Atorvastatin Calcium157$1,616
Levothyroxine Sodium159$1,453
Pravastatin Sodium43$1,220
Potassium Chloride49$1,097
Losartan Potassium129$1,036
Amlodipine Besylate185$937
Lisinopril126$909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$65,02344 claims
PfizerEliquis$143$23,25814 claims
Novo NordiskOzempic$202$14,65912 claims
Lilly USA, LLCMounjaro$106$13,85211 claims
AbbVieSynthroid$326$87614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Roeland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →